Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in adrenal cortex cells | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14649
Sealed predictions
- RAPGEF4 in dopamine neurons, braak-0.03 (p 0.944) → +0.29 (p 0.443)receipt 14656
- RAPGEF4 in oligodendrocytes, braak-0.24 (p 0.533) → +0.17 (p 0.671)receipt 14655
Swarm cases
receipt 14656: RAPGEF4 in dopamine neurons, braak
- power
- full sample +0.06 (p 0.807, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.761, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.03 (p 0.901, n 18). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.20, sign flips 4; without severely affected donors +0.06 (p 0.807, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAPGEF4 in dopamine neurons.
case closed: nothing better to follow up.
receipt 14655: RAPGEF4 in oligodendrocytes, braak
- power
- full sample -0.06 (p 0.827, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.827, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.02 (p 0.949, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.06, sign flips 4; without severely affected donors -0.06 (p 0.827, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAPGEF4 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts